ArticleJournal of immunological methods2013
Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.).
Article in Journal of immunological methods, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells.Frontiers in immunology · 2024Article
- Effective high-throughput isolation of fully human antibodies targeting infectious pathogens.Nature protocols · 2021Review
- Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.Nature medicine · 2019Article
- Techniques to Study Antigen-Specific B Cell Responses.Frontiers in immunology · 2019Review
- Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies.Frontiers in immunology · 2018Review
- Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.Virology · 2015Article
- Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Progress in HIV-1 vaccine development.The Journal of allergy and clinical immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Significant efforts have been made to identify HIV-1 neutralizing antibodies because they are considered to be critical to the design of an effective HIV-1 vaccine. Although soluble HIV-1 envelope proteins can be used for this purpose, these reagents differ from membrane-anchored HIV-1 envelope spike in a number of important ways and display only a subset of its native epitopes. Consistent with this, some broadly neutralizing antibodies preferentially bind cell surface-expressed HIV-1 envelope, but not the soluble protein. Here we report the details of a new method for isolating anti-HIV-1 specific B cells based on capturing cells that produce antibodies to cell surface-expressed gp160Δc(BaL). While this method is far less efficient than sorting with soluble envelope proteins, it isolated broadly neutralizing anti-HIV-1 antibodies that bind cell surface-expressed gp160Δc(BaL) but not soluble envelope proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.